https://bvd-523inhibitor.com/p....sychometric-properti
TECHNIQUES This analysis offers all of the preclinical and clinical data regarding tafenoquine nervous system security. Data had been put together from posted sources. The possibility of neuropsychiatric adverse events (NPAEs) with single-dose tafenoquine (300 mg) in combination with chloroquine to achieve P. vivax relapse prevention is specially analyzed. RESULTS there is no proof of neurotoxicity with tafenoquine in preclinical pet designs. In clinical researches in P. vivax r
Like
Comment
Share
